The invention relates to novel combination therapies involving BLyS or BLyS/APRIL inhibition and immunosuppressants for the treatment of autoimmune diseases. One preferred method is where the BLyS and/or APRIL antagonist is a Fc-fusion protein which can be a TACI-Fc-fusion protein comprising the extracellular domain of TACI or a functional fragment thereof a BAFF-R-Fc-fusion protein comprising the extracellular domain of BAFF-R or a functional fragment thereof or a BCMA-Fc-fusion protein compris...

The present invention relates to a pharmaceutical composition comprising azathioprine as an active ingredient for preventing or treating cancer or Temodal-resistant glioblastomas. The azathioprine according to the present invention not only effectively inhibits the proliferation of glioblastomas but also exhibits excellent effects in treating glioblastoma cancer cells that are resistant to Temodal (temozolomide) which is a conventional therapeutic agent for treating glioblastomas. Therefore the ...

The present invention provides a composition for treating and/or preventing type I diabetes and an application thereof. The active ingredient of the composition is 1.) or 2.) or 3.) as follows: 1.) a mixture of a type I diabetes protein antigen and an immunosuppressor 2.) a mixture of a type I diabetes protein antigenic epitope polypeptide and an immunosuppressor 3.) a mixture of a type I diabetes protein antigen a type I diabetes protein antigenic epitope polypeptide and an immunosuppressor; th...

In the present invention there are described soluble CTLA4 fusion molecules containing extracellular domain of the CTLA4 molecule and their use optionally in combination with a second agent being selected from the group consisting of corticosteroids nonsteroidal anti-inflammatory agents cyclosporine prednisone azathioprine methotrexate TNF-alpha blockers or antagonists hydroxychloroquine sulphasalazine gold salts anakinra cyclophosphamide and leflunomide and their use as well as pharmaceutical c...

PURPOSE: A pharmaceutical composition for treating lupus nephritis including thalidomide or lenalidomide is provided to prevent lupus nephritis by reducing the amount of proteinuria in a lupus nephritis animal model. CONSTITUTION: A pharmaceutical composition for treating lupus nephritis including thalidomide or lenalidomide comprises a thalidomide or a lenalidomide. The pharmaceutical composition additionally includes a corticosteroid The pharmaceutical composition additionally includes at leas...

The present invention relates to the use of a combination of azathioprine (AZA) and L- buthionine-[SR]-sulfoximine (BSO) or the pharmaceutically suitable salts thereof in the preparation of a drug useful in the treatment of a refractory tumor preferably cancer. The combination in the invention has been shown to be especially effective in particular in the treatment of solid tumors of the liver colon and colon metastasis to the liver tumors that are highly resistant to chemotherapy. The invention...